Drug Type Small molecule drug |
Synonyms Vamifeport |
Target |
Mechanism FPN1 inhibitors(Ferroportin-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H21FN6O2 |
InChIKeyKNYVRFXIVWUGBZ-UHFFFAOYSA-N |
CAS Registry2095668-10-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-transfusion dependent thalassaemia | Phase 3 | GR | 11 Jun 2020 | |
Non-transfusion dependent thalassaemia | Phase 3 | LB | 11 Jun 2020 | |
Non-transfusion dependent thalassaemia | Phase 3 | IT | 11 Jun 2020 | |
Beta-Thalassemia | Phase 2 | GR | 11 Jun 2020 | |
Beta-Thalassemia | Phase 2 | GR | 11 Jun 2020 | |
Thalassemia | Phase 2 | - | - | |
Beta-Thalassemia | Preclinical | IT | 11 Jun 2020 | |
Non-transfusion dependent thalassaemia | Discovery | TH | 11 Jun 2020 | |
Non-transfusion dependent thalassaemia | Discovery | IL | 11 Jun 2020 | |
Iron Overload | Discovery | GR | 03 Mar 2020 |
NCT04364269 (EHA2022) Manual | Phase 2 | 25 | (ggwfmbxtlp) = mjzznkmnys ykzkptsroz (vnbbmhrbfw ) View more | Positive | 12 May 2022 | ||
(mpttyarclg) = tpiskauhro nnxruypzts (qdxpjnrolt ) View more | |||||||
Phase 2 | 35 | Placebo | (inyrnxfnly) = hhulkxfkas kknddqragu (fulpgpgjpe, rwuperjjfh - dbpszngkwc) View more | - | 14 Dec 2023 |